Cemiplimab: a new option for the treatment of non-small-cell lung cancer.
暂无分享，去创建一个
[1] A. Ardizzoni,et al. PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: the role of salvage chemo-immunotherapy combination. , 2021, Immunotherapy.
[2] A. Brandes,et al. Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. , 2021, Immunotherapy.
[3] B. Clotet,et al. Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study. , 2020, JAMA oncology.
[4] D. Costa,et al. Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. , 2020, Lung cancer.
[5] F. Cappuzzo,et al. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. , 2019, Lung cancer.